Key result
Statin use significantly reduced the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma compared to no statin use (HR 0.36; 95% CI 0.15-0.82; p=0.015).
Why the study?
Does statin use reduce the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma?
Cohort (n=532)
Does statin use reduce the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma?
Early statin use may significantly reduce the risk of postradiotherapy epilepsy in patients with nasopharyngeal carcinoma.
May support statin consideration post-radiation; hypothesis-generating from Level 3 data and requires randomized confirmation.
OBJECTIVE: This study aimed to clarify the effect of statins on preventing the risk of postradiation epilepsy. METHODS: We performed a retrospective analysis of neurological nasopharyngeal carcinoma patients with a history of radiotherapy. Patients with a history of epilepsy before radiation and those who received prophylactically antiepileptic treatment were excluded. The demographic and clinical data of these patients were collected through chart review. We used Kaplan-Meier analysis (log-rank test) to examine the effect of statins on epilepsy-free survival. Cox regression analysis was utilized to identify independent predictive variables. RESULTS: Our study included 532 patients (405 males and 127 females) with a mean follow-up of 28.1 months. During follow-up, 471 (88.5%) patients developed radiation-induced brain necrosis (RN). Within a mean latency of 24.1 months, 88 (16.5%) patients experienced epilepsy, of whom 27 (27 of 88, 30.7%) patients suffered from epilepsy before the diagnosis of RN. Thirty-six (36 of 88, 40.9%) cases of epilepsy occurred after RN onset, and in 22 cases (22 of 88, 25.0%) epilepsy was the first presentation of RN. Three patients suffered from epilepsy but did not have RN. Eighty-eight patients in our cohort were treated with statins because of hyperlipidemia or prevention of cardiocerebrovascular diseases, of whom six (6.8%) developed epilepsy, whereas in those without statin, the epileptic rate was 18.5%. Log-rank test found that there was a significant difference in epilepsy-free survival between patients who used statins and those who did not (p = 0.016). After adjusting for confounding variables, multivariate Cox regression analysis revealed that statin use could still significantly reduce the risk of epilepsy after radiation (hazard ratio = 0.36, 95% confidence interval = 0.15-0.82, p = 0.015). However, for the patients who already suffered from RN, statin treatment did not lower the risk of post-RN epilepsy. SIGNIFICANCE: Early statin use may reduce the risk of postradiotherapy epilepsy in patients with nasopharyngeal carcinoma.
No takes yet. Share an insight, caveat, or question.
Rong et al. (2017) conducted a cohort in Nasopharyngeal carcinoma with a history of radiotherapy (n=532). Statins vs. No statin use was evaluated on Postradiation epilepsy (HR 0.36, 95% CI 0.15-0.82, p=0.015). Statin use significantly reduced the risk of postradiation epilepsy in patients with nasopharyngeal carcinoma compared to no statin use (HR 0.36; 95% CI 0.15-0.82; p=0.015).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: